After participating in this educational activity, attendees should be able to:
1| Review FDA-approved indications and mechanism of action of colchicine
2| Evaluate relevant literature that set a precedent for the approval of colchicine (Lodoco)
3| Define the place in therapy of colchicine for CAD patients
4| Compare and discuss conflicting literature regarding the utility of colchicine in acute ACS
Ashley M Varela Martinez, PharmD
PGY1 Community Based Pharmacy Resident
Baystate Medical Center 
Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 


Accreditation Statement
In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Baystate Health designates this activity for a maximum of 1.0 contact hours (s) for pharmacists. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. 


Session date: 
02/26/2024 - 2:00pm to 3:00pm EST
United States
  • 1.00 ACPE Contact Hours
  • 1.00 BCIPE Instructional Hours

Please login or register to take this course.